James N. Ingle, MD | Authors

Endocrine Therapy in 2009: Consideration of the Tumor and the Host

February 18, 2009

Breast cancer is the most common female malignancy in the Western world. Two-thirds of all breast cancers are estrogen receptor (ER)-positive, a phenotypic characteristic that is prognostic of disease-free survival and predictive of response to endocrine therapy.

Aromatase Inhibition and Antiestrogen Therapy in Early Breast Cancer Treatment and Chemoprevention

May 01, 2001

The aromatase inhibitors represent an important class of hormonal agents for the management of breast cancer. The third-generation aromatase inhibitors have replaced megestrol acetate as second-line hormonal